Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC

Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 71.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 457,322 shares of the company’s stock after selling 1,141,944 shares during the quarter. Almitas Capital LLC owned 0.63% of Zentalis Pharmaceuticals worth $691,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Algert Global LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $73,000. Creative Planning increased its position in Zentalis Pharmaceuticals by 757.0% during the 3rd quarter. Creative Planning now owns 260,000 shares of the company’s stock worth $393,000 after purchasing an additional 229,660 shares in the last quarter. Two Sigma Investments LP raised its holdings in Zentalis Pharmaceuticals by 24.7% in the third quarter. Two Sigma Investments LP now owns 1,363,347 shares of the company’s stock valued at $2,059,000 after buying an additional 270,294 shares during the period. UBS Group AG raised its holdings in Zentalis Pharmaceuticals by 311.4% in the third quarter. UBS Group AG now owns 532,678 shares of the company’s stock valued at $804,000 after buying an additional 403,210 shares during the period. Finally, Vanguard Group Inc. lifted its position in Zentalis Pharmaceuticals by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares in the last quarter.

Zentalis Pharmaceuticals Trading Down 1.5%

Zentalis Pharmaceuticals stock opened at $2.71 on Friday. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $3.95. The stock has a market cap of $195.80 million, a P/E ratio of -1.31 and a beta of 1.71. The stock has a 50 day moving average of $2.63 and a 200-day moving average of $1.89.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.00.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters bought 6,459,973 shares of the business’s stock in a transaction dated Wednesday, December 31st. The shares were acquired at an average price of $1.20 per share, for a total transaction of $7,751,967.60. Following the purchase, the insider owned 13,509,973 shares in the company, valued at $16,211,967.60. This trade represents a 91.63% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the completion of the sale, the insider owned 6,459,973 shares in the company, valued at approximately $8,591,764.09. This trade represents a 53.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,546,617 shares of company stock worth $10,088,417 in the last ninety days. 1.90% of the stock is owned by insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.